| Followers | 834 |
| Posts | 119880 |
| Boards Moderated | 17 |
| Alias Born | 09/05/2002 |
Thursday, July 21, 2011 1:09:20 AM
CML Drug Market is ‘Sticky’
This chart from NVS’ 2Q11 CC shows how hard is it for
Tasigna to make inroads against Gleevec, even though Tasigna
showed statsig superiority to Gleevec in randomized phase-3
trials and both drugs are marketed by the same company.
Source: http://www.novartis.com/downloads/investors/event-calendar/2011/2011-07-novartis-q2-presentation.pdf (slide #35)
This chart from NVS’ 2Q11 CC shows how hard is it for
Tasigna to make inroads against Gleevec, even though Tasigna
showed statsig superiority to Gleevec in randomized phase-3
trials and both drugs are marketed by the same company.
Source: http://www.novartis.com/downloads/investors/event-calendar/2011/2011-07-novartis-q2-presentation.pdf (slide #35)
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
